Galectin Therapeutics Inc. (GALT)

[Chess Master]

Lets distill down to the root of what when wrong in the FX trial. The trial was poorly designed first of all with no dose escalation and their endpoints were using non invasive tests that simply don't work on people with BMI over 35%. They were designed to work on Hep C patients who didn't have a fatty liver. the gold standard is the Liver biopsy and the FX patients probably got better but we don't know that and cant prove that because they didn't do a liver biopsy. Now if they put in the protocol a liver biopsy at a years time we might have data starting to come in that shows well maybe it was a success afterall. But that wasn't done was it? Again, this was a complete waste of shareholders money and I think the board needs to take action against those responsible for this miscue. So 10% chance of the CX trial succeeding is not generous but ludicrous. Its probably a 90% chance of success because they have data points that use the gold standard of liver biopsy. You cannot idly sit by and see how successful the psoriasis trial was and not see that there is clearly biological activity surrounding the Gal-3 target. I mean when you have PI initiated trials like the Atopic Dermatitis its kind of embarrassing for mgt to sit there and see support for a trial that they abandoned. Lets face reality our team sucks and is way overpaid. But the drug is the real deal.